Oncothyreon (ONTY), Commercial Vehicle Group (CVGI), Deltek (PROJ) and Century Aluminum (CENX) took advantage this morning of a strengthening U.S. manufacturing sector and a slight rise in construction spending to follow the markets upward trends.
In the midst of the surge, Oncothyreon (ONTY) http://www.oncothyreon.com/ announced positive Phase III Trial data today and posted a 25.49% gain ($1.18) in early trading. ONTY is currently trading on the Nasdaq in the $5.86 range with a new market cap of $114 million. ONTY has a 3-Month average daily trading volume of 408,183 shares and by 11 a.m. EST, ONTY had easily quadrupled that number surpassing 1,955,674 shares traded.
ONTY management said today that clinical data relating to long-term treatment with its Stimuvax drug was presented at the International Association for the Study of Lung Cancer's 13th World Conference on Lung Cancer in San Francisco on Saturday.
Prolonged treatment with Stimuvax was well-tolerated by patients in this part of the trial. A big plus. Merck KGaA (in Germany) is responsible for the world-wide development and commercialization of Stimuvax under license from ONTY and is currently conducting Phase 3 trials of Stimuvax in two other types of cancer.
ONTY is a clinical-stage biopharmaceutical company and has an impressive pipeline including PX-478 and PX-866 in Phase I Trials, PX-316 and PX-12, a Phase II trial product for pancreatic cancer and ONTY has BGLP40 Liposome Vaccine, a preclinical stage liposomal glycolipopeptide cancer vaccine.
At $5.86, ONTY will set a new 52-week high today. ONTY has a 52-week low of $0.62 set on 10-08-08. At $5.86, ONTY is above both its 50-day and 200-day moving averages. ONTY has trailing twelve month revenues of $19.5 million and a trailing twelve month diluted EPS of $0.50. It shares out versus float ratio is at parity.
Also posting a big gain today; 23.88% ($0.48), is Commercial Vehicle Group (CVGI) http://www.cvgrp.com/ now trading on the Nasdaq in the $2.50 range with a new market cap of $51 million. CVGI has a 3-Month average daily trading volume of 315,965 shares and it topped 586,226 shares by 11 a.m. EST.
In addition to the market at large, I believe the jump today is due to the anticipation of investors about the CVGI earnings conference call this Wednesday at 10 a.m. EST. CVGI is part of the hard hit Auto Parts sector, but its activities in the last 30 days could bode well for the call.
For example, on July 9, CVGI announced it had been selected as the Development Source Partner for a new seat and suspension program with Nissan Diesel Motors. The primary markets will be Japan, South America, Asia, Australia and the U.S. On May 21, CVGI management adopted a Stockholder Rights Plan that will help protect stockholders against takeover tactics that may be used to gain control of the Company without paying a full and fair price that is in the best interest of CVGI shareholders. Good move.
The primary business at CVGI is seats and seating systems, including air suspension seats, static seats, bus seats, heavy truck seats, and construction and other commercial vehicle seats. CVGI also provides trim systems and components for the interior cabs of commercial vehicles, which include instrument panels, door panels, headliners/wall panels the third leg of CVGI revenues is mirrors and windshield wiper systems; electronic wire harnesses and panel assemblies.
At $2.50, CVGI is far, far below its 52-week high of $11.49 set on 09-22-08 and five times above its low of $0.40 set on 03-09-09. At $2.50, CVGI is ahead of both its 50-day and 200-day moving average. CVGI has trailing twelve month revenues of $675 million. Its shares out versus float ratio is near-parity. Remember; buy low, sell high.
Well with last Thursday's headlines of "License Revenue Increases 40%, Net Income Increases 85% from Prior Quarter" its no wonder that Deltek Inc., (PROJ) http://www.deltek.com/ is still on a roll. PROJ gained 13.85% ($0.86) in early trading today. PROJ is currently trading in the $7.11 range with a new market cap of $314 million. PROJ easily doubled its 3-Month average daily trading volume of 112,585 shares to top 268,355 shares traded by 11 a.m. EST.
PROJ reported on July 30 that total revenue for Q2 was $69.4 million, an increase of 12% from Q1. PROJ reported Q2 license revenue increased 40% from Q1 to $15.8 million. Other revenues in Q2 increased to $3.4 million from $0.1 million in Q1. And the most important for investors: Q2 net income increased 85% to $4.9 million, or $0.09 per diluted share, from $2.7 million, or $0.06 per diluted share, in Q1. Strong numbers.
PROJ products include Costpoint, a financial management solution that tracks, manages, and reports on key aspects of a project, including planning, estimating, proposals, budgets, expenses, indirect costs, purchasing, billing, regulatory compliance, and materials management. It also has three other variations: Vision, GCS Premier and Open Plan.
At $7.11, PROJ is below its 52-week high of $9.05 set on 08-15-08 and above its 52-week low of $2.90 set on 02-13-09 (a good buy signal). At $7.11, PROJ is ahead of both its 50-day and 200-day moving averages. PROJ has trailing twelve month revenues of $282 million and a trailing twelve month diluted EPS of $0.50. Insiders hold a lot of this stock and I would like to see more shares in the public float for stability.
And finally, S&P SmallCap 600 company Century Aluminum Company (CENX) http://www.centuryaluminum.com/ had a nice 10.62% gain this morning ($0.89) as the sector Big Caps like Alcoa (NYSE:AA) and Kaiser (NASDAQ:KALU) gave some hope to embattled aluminum investors. One of the hardest hit sectors during the recession, aluminum companies, like CENX, were forced to severely cut capacity and workforces.
CENX reported on July 23 that it had a Q2 net loss of 46 cents per share. Ouch. Currently trading (with its gain today) in the $9.27 range on the Nasdaq, CENX has a new market cap of 687 million. CENX had nearly halved its 3-Month average daily trading volume of 5,842,540 shares by 11 a.m. EST.
At $9.27, CENX is far, far below its 52-week high of $59.60 set on 08-01-08 and far, far above its 52-week low of $1.04 set on 03-09-09 (another good buy signal). At $9.27, CENX is above both its 50-day and 200-day moving averages. CENX has trailing twelve month revenues of $1.37 billion and its shares out versus float ratio is a little lopsided, but it isn't a red flag for stability or liquidity.